Codexis Reports Q1 2026 Revenue Up 103% to $15.2M
Codexis (NASDAQ:CDXS) reported Q1 2026 revenue of $15.2 million, up 103% from $7.5 million a year ago, driven by its ECO Synthesis enzymatic manufacturing platform for RNA medicines. The company reaffirmed its full-year revenue guidance of $72 million.
Key Numbers
Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, a 103% increase from $7.5 million in the same period last year. The company attributed the growth to continued progress in commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines.
Key Financial Results
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $15.2M | $7.5M | +103% |
| Net Income | Not disclosed | Not disclosed | - |
| EPS | Not disclosed | Not disclosed | - |
Note: The company did not disclose net income or EPS in the announcement.
Highlights from the Statement
Management noted increasing demand from pharmaceutical companies for RNA-based drugs, which is driving adoption of the ECO Synthesis platform.
Future Guidance
Codexis reaffirmed its full-year 2026 revenue guidance of $72 million, signaling confidence in sustained momentum.
Stock Impact
The stock showed no major immediate movement, but analysts view the guidance reaffirmation as a positive signal for market confidence.
What This Means for Investors
The strong Q1 performance demonstrates Codexis's ability to execute its strategy in the fast-growing RNA medicine market. However, investors should monitor whether the company meets its annual guidance and track competitive developments.
Frequently Asked Questions
Found this useful? Share it